Objective. To determine the dose response effect of weight loss on clinical and mechanistic outcomes in overweight and obese adults with knee osteoarthritis (OA). Methods. This is a secondary analysis of the diet-induced weight loss only (D) and diet-induced weight loss plus exercise (D + E) groups in the Intensive Diet and Exercise for Arthritis randomized controlled clinical trial. The 240 participants were overweight and obese older community-dwelling adults with pain and radiographic knee OA. Participants were assigned to 1 of 4 groups according to weight loss achieved over an 18-month period: <5% (<5% group), 5-10% (≥5% group), 10-20% (≥10% group), and >20% (≥20% group).
INTRODUCTION
Obesity is a health issue worldwide and a major and modifiable risk factor for many of the more than 250 million people with knee osteoarthritis (OA) (1) (2) (3) (4) . Previous weight loss studies in overweight and obese adults with knee OA conducted in highly controlled (5) and community-based environments (6) showed similar significant responses; 10% weight loss resulted in less pain, better function, improved health-related quality of life (HRQoL), reduced knee joint loads, and less inflammation compared with no weight loss or <10% weight loss. These data are consistent with the National Institutes of Health (NIH) recommendation for overweight and obese adults to lose 10% of baseline weight as an initial goal (7) . Moreover, recent observational data from the Osteoarthritis Initiative indicate that greater weight loss is associated with less cartilage degradation (8) .
ClinicalTrials.gov identifier: NCT00381290. Supported by the NIH (grant R01-AR-052528-01 from the National Institute of Arthritis and Musculoskeletal and Skin Diseases, grant P30-A21332 from the National Institute on Aging, grant M01-RR-00211 from the National Center of Research Resources), and General Nutrition Centers, Inc. 1 Most randomized controlled weight loss trials in older overweight and obese adults with knee OA showed weight reduction of 5-10% after 1-2 years (5,9,10). Data from the National Weight Control Registry indicate that some patients lose more than twice that amount and maintain the reduction (9, (11) (12) (13) (14) (15) . However, whether weight loss of this magnitude can be achieved nonsurgically under randomized clinical trial conditions, and whether there is any benefit beyond what has been shown with 10% weight loss in a population of patients with knee OA, are unknown.
Achieving significant weight loss without regaining the weight is difficult. The body acts in starvation mode, increasing feelings of hunger. Starvation mode suppresses satiety, slows the metabolic rate, and attempts to defend higher body weights (16) . Therefore, to justify the effort needed by patients to achieve a more substantial intentional weight loss than what has been proven to be effective in randomized clinical trials, the outcomes should be significantly better with minimal adverse side effects (5, 6, 10) . We performed a secondary analysis of the weight loss groups in our Intensive Diet and Exercise for Arthritis (IDEA) trial (diet only [D] and diet plus exercise [D + E]) to determine whether participants who lost twice the average weight loss as that in the ≥10% group had significantly better clinical and mechanistic outcomes at the 18-month follow-up. We hypothesized that participants who lost ≥20% of baseline body weight would have significantly reduced pain, knee joint loads, and systemic inflammation as well as improved function and HRQoL compared with participants who lost <5%, 5-9.9%, or 10-19.9% of their baseline body weight.
SUBJECTS AND METHODS
Study design. IDEA was a single-blind, single-center, 18-month, randomized controlled trial conducted at Wake Forest University and Wake Forest School of Medicine between July 2006 and April 2011. Participants were randomized into 1 of 3 groups: D, D + E, or exercise (E). Data from group D and group D + E were used for this doseresponse analysis. The trial design and rationale and the primary outcomes of the trial are detailed elsewhere (5, 17) . The study was approved by the Human Subjects Committee of Wake Forest Health Sciences. All participants provided both verbal and written consent.
Study sample. The sample consisted of ambulatory community-dwelling persons ages ≥55 years with: 1) Kellgren/ Lawrence (K/L) grade 2 or 3 (mild or moderate) radiographic tibiofemoral OA or tibiofemoral plus patellofemoral OA in 1 or both knees (18) , 2) pain on most days due to knee OA, 3) 27 kg/m 2 ≤ body mass index (BMI) ≤41 kg/m 2 , and 4) a sedentary lifestyle (<30 minutes/week of formal exercise for the past 6 months). Participants maintained and adjusted their usual medications as needed, with their physicians' consent. Participants in the D + E group and the D group were classified into weight loss categories based on percent loss in body weight at 18 months, according to the following categories: <5% weight loss (<5% group), 5-9.9% weight loss (≥5% group), 10-19.9% weight loss (≥10% group), and 20% and greater weight loss (≥20% group). The ≥5% and ≥10% weight loss categories reflect the weight loss goals achieved in Arthritis, Diet, and Activity Promotion Trial (ADAPT) (9) and IDEA (5), respectively; ≥20% weight loss was twice that in IDEA, and in ADAPT, the ≤5% group was considered to not have achieved a significant weight loss compared with the control group.
Interventions. The D group received the dietary weight loss intervention, and the D + E group received both diet and exercise interventions. The goal of the intensive weight loss intervention was a mean group loss of at least 10% of baseline body weight, with a desired range of 10-15%. The diet was based on partial meal replacements, including up to 2 meal-replacement shakes per day (Lean Shake, provided by General Nutrition Centers, Inc.). For the third meal, participants followed a weekly menu plan with recipes that provided 500-750 kcal, were low in fat, and were abundant in vegetables. Daily caloric intake was adjusted according to the rate of weight change between intervention visits.
The initial diet plan provided an energy-intake deficit of 800-1,000 kcal/day, as predicted by energy expenditure (estimated resting metabolism 9 1.2 activity factor), with at least 1,100 kcal for women and 1,200 kcal for men. The calorie distribution goal was 15-20% from protein, <30% from fat, and 45-60% from carbohydrates, which is consistent with the Dietary Reference Intakes for Energy and Macronutrients (19) and successful weight loss programs (20) . As follow-up progressed, fewer meal replacements were consumed. Body weight was monitored weekly or biweekly during nutrition education and behavioral sessions developed within a social cognitive theory framework: from month 1 to month 6, 1 individual session and 3 group sessions per month, and from month 7 to month 18, biweekly group sessions and an individual session every 2 months (21, 22) . A more detailed discussion of the dietary intervention is available elsewhere (5, 23) . A loss of >20% body weight after 6 months or >30% after 12 months triggered a weight-related safety alert.
Significance & Innovations
• Relatively large differences in intentional, nonpharmacologic, nonsurgical weight loss produce large and beneficial differences in clinical and mechanistic outcomes.
• The significant dose response to weight loss in pain, inflammation, knee joint loads, function, mobility, and health-related quality of life outweighs the slight reduction in bone mineral density that accompanies a weight loss of ≥10% or ≥20% of baseline body weight.
• The standard of care for older overweight and obese adults with knee OA should include, at minimum, a 10% weight loss.
• Losing 20% compared with 10% of baseline body weight in overweight and obese adults with knee OA has the added benefit of significantly improved physical health-related quality of life and a 25% reduction in pain and improvement in function.
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The exercise intervention was conducted for 1 hour 3 days weekly for 18 months and was supervised by trained interventionists, most of whom held American College of Sports Medicine certification. The program consisted of aerobic walking (15 minutes), strength training (20 minutes), a second aerobic phase (15 minutes), and cool-down (10 minutes).
Measurements and procedures. All participants were tested at baseline, 6-month follow-up, and 18-month follow-up. An initial symptom-limited, maximum exercise stress test excluded anyone with severe manifestations of coronary heart disease. The Modified Mini-Mental State Exam was used to screen for cognitive deficiencies (24) . Knee OA is an active disease process with joint destruction driven by both biomechanical and proinflammatory factors (25) . We used bone-on-bone knee joint compressive forces and interleukin-6 (IL-6) level as the primary biomechanical and inflammation outcomes, respectively.
Knee joint load. Bone-on-bone peak tibiofemoral (knee) compressive force (in Newtons) was the primary measure of knee joint loading. A detailed description of the instruments used to measure and calculate knee joint compressive force is available elsewhere (26) .
Plasma IL-6. Blood samples were collected in the early morning after a 10-hour fast, at baseline, 6-month followup, and 18-month follow-up. The 6-month and 18-month samples were collected at least 24 hours after the last "acute bout" of exercise training (D + E group), and sampling was postponed (1-2 weeks after recovery from symptoms) in the event of an acute respiratory, urinary tract, or other infection. All blood was collected, processed, divided into aliquots, and stored at À80°C until analyzed.
The inflammation measure was the plasma IL-6 level (in pg/ml). All samples were measured in duplicate using enzyme-linked immunosorbent assays (Quantikine ELISA Kits; R&D Systems), and the average values were used for data analyses.
Pain. The Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale was used to measure self-reported pain (27, 28) . Using this instrument, subjects indicate on a scale from 0 (none) to 4 (extreme) the degree of pain (due to knee OA) experienced while performing activities of daily living during the last 48 hours. Total scores for the 5 items range from 0 to 20, with higher scores indicating greater pain.
Function and mobility. Individual scores for the 17 items of the WOMAC self-reported function subscale were added to generate a summary score ranging from 0 to 68, with higher scores indicating poorer function. The 6-minute walk distance (in meters) was used to measure mobility.
Weight, height, BMI, and health-related quality of life (HRQoL). Weight, height, and BMI were measured using standard techniques. The Short Form 36 (SF-36) was used to measure HRQoL, using 2 broad summary scores: physical health and mental health, where 0 = worst and 100 = best (29) .
Body composition and bone mineral density (BMD). Total body lean mass, total body fat mass, and BMD were measured at baseline and 18-month follow-up, by dual x-ray absorptiometry using a fan-beam scanner (Delphi A; Hologic), according to the manufacturer's recommendations for patient positioning, scanning, and analysis.
Radiography. We used bilateral, posteroanterior, weightbearing knee radiographs to identify tibiofemoral OA and sunrise views to identify patellofemoral OA. To visualize the tibiofemoral joint, we used a positioning device to flex knees 15 degrees, with the beam centered on the joint space. The K/L grade (scale 0-4) was used to quantify the severity of tibiofemoral OA (18) .
Physical Activity Scale for the Elderly (PASE). The PASE scale was used to assess self-reported daily physical activity during a 7-day period prior to baseline and followup testing (30, 31) .
Statistical analysis. The baseline characteristics of the participants, overall and according to weight loss categories, were summarized using means and SDs for continuous variables and frequencies and percentages for categorical variables. Tests for heterogeneity of weight loss group characteristics at baseline were performed using one-way analysis of variance for continuous variables and chi-square tests for categorical variables. Outcomes were modeled using a linear mixed model using 6-month and 18-month follow-up data, with main effects of weight loss category, visit code, and weight loss category by visit interaction adjusted for baseline BMI, sex, treatment assignment (D or D + E), and baseline values for the outcome. Substitution of baseline body weight for baseline BMI as a covariate did not alter the outcomes (data not shown). Tests for the outcomes at 18 months were performed using contrast statements. P values less than 0.05 were considered significant for the main weight loss category effect. Significant pairwise comparisons were noted at a conservative Bonferroni-adjusted significance level of 0.0125. All analyses were conducted using SAS version 9.4. Table 1 shows the baseline characteristics of the weight loss groups. There were no significant baseline differences in age, BMI, or weight between the groups. The majority of participants were female and white.
RESULTS
Weight loss and body composition. The mean percent weight changes from lowest to highest weight loss group were 0.2% (n = 74), 7.4% (n = 59), 14.5% (n = 76), and 24.6% (n = 31), respectively. Total body fat increased by 0.44 kg in the <5% group and decreased by 3.29 kg, 7.97 kg, and 14.44 kg in the ≥5%, ≥10%, and ≥20% weight loss groups, respectively. These changes in body composition resulted in alterations in the BMI of +0.1, À2.4, À4.7, and À8.1 kg/m 2 , respectively. Figure 1 shows the distribution of weight loss across all categories and participants. The variables weight, BMI, and total hip and femoral neck BMD at the 18-month follow-up (adjusted for visit, sex, treatment arm, and baseline values) and lean and fat mass (adjusted for sex, treatment arm, and baseline values) all exhibited significant dose responses (Table 2) . Dose response to weight loss. Clinical outcomes. There was a significant (P = 0.006) dose response for WOMAC pain scores; pairwise comparisons at the 18-month followup showed that the ≥20% group had significantly less pain compared with the <5% group (P = 0.003) and the ≥5% group (P = 0.002). There was a similar significant dose response (P = 0.0005) to weight loss in WOMAC function scores; the ≥20% group had better function compared with the <5% group (P = 0.0003) and the ≥5% group (P = 0.0006). The ≥10% group also had better function compared with the <5% group (P = 0.007); there was no significant difference in WOMAC pain or function scores between the ≥10% and ≥20% groups (Tables 3 and 4) .
The 6-minute walk distance was significantly (P < 0.0001) impacted by the amount of weight loss (Table 3) . Both the ≥20% and ≥10% groups walked significantly farther than the 2 lowest weight loss groups (for ≥20% versus <5%, P < 0.0001; for ≥20% versus ≥5%, P = 0.0003; for ≥10% versus <5%, P = 0.0001; for ≥10% versus ≥5%, P = 0.0112) ( Table 4) . Both the physical (P = 0.001) and mental (P = 0.02) subscales of the SF-36 were affected by the amount of weight loss ( Table 3 ). The ≥20% group had significantly improved physical HRQoL compared with the 3 lower weight loss categories (for ≥20% versus <5%, P < 0.0001; for ≥20% versus ≥5%, P = 0.0008; for ≥20% versus ≥10%, P = 0.002). Improvement in mental HRQoL was similar between the weight loss groups (Table 4 ). There was no significant dose response for the PASE activity scale (P = 0.083).
Mechanistic outcomes. The IL-6 level, our primary inflammation outcome, was significantly different among the weight loss groups (P = 0.017) ( Table 3 ). The highest weight loss group had decreased IL-6 levels compared with the lowest weight loss group (for ≥20% versus <5%, P = 0.002.
Bone-on-bone knee joint compressive forces showed a distinct dose response to weight loss (P < 0.0001). Compressive forces in the ≥20% group were attenuated by 244 Newtons (55 pounds), 400 Newtons (92 pounds), and 550 Newtons (124 pounds) compared with the ≥10% (P = 0.02), ≥5% (P = 0.0003), and <5% (P < 0.0001) groups, respectively. The ≥10% group also demonstrated lower compressive forces compared with the <5% group (P = 0.0006) ( Table 4) . Table 3 . Dose-response effect of weight loss on outcome measures at the 18-month follow-up, according to percent weight loss* <5% (n = 74) 
DISCUSSION
Moderate (5%) to intensive (10%) weight loss in older overweight and obese adults with knee OA has positive effects on clinical and mechanistic outcomes, with a clear doseresponse effect (5, 6, 9, 10) . Our participants who reached their weight loss goal of 10% and expressed a desire to continue to lose weight were monitored by the study team to ensure that additional weight loss was achieved safely. Consequently, 13% of participants in all weight loss groups combined safely lost >20% of their baseline body weight. Two participants triggered weight-related safety alerts by losing >20% of their baseline weight in 6 months or >30% in 12 months. In these 2 cases, the study physician contacted the participants and questioned them about clinical symptoms that would indicate safety or health issues. Additionally, intervention staff continued to monitor weight loss, physical activity, and dietary behaviors to look for indications of disordered eating patterns and excessive levels of exercise.
Significant pairwise differences between the ≥10% group and the ≥20% group were limited to improvement in physical HRQoL, due in part to the small sample size in the more extreme weight loss group (i.e., possible Type II error). However, the strong trend for pain (P = 0.06) and function (P = 0.0005) (see Table 3 ) across weight loss groups combined with a clinically important 25% mean reduction in pain and improvement in function when progressing from 10% weight loss to 20% weight loss suggests that greater weight loss may have additional clinical value. Therefore, although our results and clinical trial data (4,5) support the NIH recommendation of an initial weight loss of 10% for overweight and obese adults with knee OA (6, 24) , the added benefit of substantially greater weight loss, achieved safely and without pharmacologic or surgical intervention, is an intriguing possibility that warrants further study.
Pairwise comparisons between the <5% group and the ≥5% group revealed no statistical difference. This is surprising considering that the D + E group in the ADAPT trial, with a 5.7% reduction in body weight, was statistically and clinically better in terms of function, mobility, and pain after an 18-month intervention compared with a healthy lifestyle control group in which participants lost 1.2% of their body weight (9) . This suggests that participation in long-term diet or diet plus exercise interventions provides some clinical benefit regardless of weight loss success. Interestingly, the mortality risk 8 years postintervention in ADAPT participants randomized to the D and D + E groups, irrespective of the amount of weight loss achieved, was statistically lower than that in participants randomized to non-weight loss groups (32) .
Significant weight loss in older adults could exacerbate bone loss and increase the risk of hip fracture (33); however, obesity increases the loads on lower extremity bones and therefore is somewhat protective in this population. Data from NHANES III defined osteopenia for men and women as between 0.56 gm/cm 2 and 0.74 gm/cm 2 for the femoral neck, and between 0.64 gm/cm 2 and 0.82 gm/cm 2 for total hip BMD (34) . There was a significant dose response to weight loss for BMD; however, mean values at the 18-month follow-up remained above the osteopenia threshold levels for all weight loss categories. We suggest that the significant reduction in pain, inflammation, and knee joint load combined with significant improvements in function, mobility, and HRQoL outweighs the slight reduction in BMD that accompanies a weight loss of ≥10% or ≥20% of baseline body weight.
Brownell effectively summarized the biologic factors that work against achieving and maintaining significant weight loss: the body acts in starvation mode, increases feelings of hunger, suppresses satiety, slows the metabolic rate, and attempts at all costs to defend higher body weights (16) . However, it is possible to achieve and maintain significant weight loss (13) . Previous work indicates that habits that distinguish successful from unsuccessful weight loss include maintaining a low-calorie, low-fat diet, high levels of physical activity, frequent weighing, and routinely eating breakfast (13) . Enhanced self-efficacy and the ability to tolerate feelings of hunger are psychological characteristics that also appear to help achieve and maintain weight loss (35) . Whether particular psychological characteristics differentiated the 13% of the diet groups that were able to achieve >20% weight loss, and whether these characteristics improve the ability to resist weight regain are unknown. Finally, our study was limited by its observational design and small sample size in the ≥20% group. Group assignment was not random but rather was based on weight loss achieved in a previous randomized clinical trial in which the goal was to lose at least 10% of baseline weight.
In summary, both ≥10% and ≥20% weight loss have substantial clinical and mechanistic benefits compared with less weight loss. We suggest that the standard of care for older overweight and obese adults with knee OA should include, at minimum, a 10% weight loss using the techniques developed in previous successful weight loss trials such as IDEA and Osteoarthritis Healthy Weight for Life. An additional 10% weight loss has the added benefit of significantly improved physical HRQoL and a clinically important reduction in pain and improvement in function.
